Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 773 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cardiovascular Disease Prevention Clear all
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

NCT04739059
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
CSL312
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 14, 2026, 6:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk

NCT05174286
View directory record Official record
Conditions
Colorectal Cancer
Interventions
SBIRT, Referral as Usual (RAU)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older
Enrollment
880 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 14, 2026, 6:18 PM EDT
Recruiting Phase 3 Interventional

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

NCT07015905
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
REGN7508, Apixaban, Enoxaparin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Sheffield, Alabama • Riverside, California • Englewood, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 6:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pulses: Optimizing Pulse Consumption for Cardiometabolic Health

NCT06861153
View directory record Official record
Conditions
Cardiovascular (CV) Risk, Healthy Eating Index, HbA1c, Lipid Profile, CRP
Interventions
Pulses 1.5 cups Group, Pulses 3 cups Group, My Plate Group (Control)
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 14, 2026, 6:18 PM EDT
Completed Phase 1Phase 2 Interventional

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

NCT00064311
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
ravuconazole
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 14, 2026, 6:18 PM EDT
Not listed Phase 3 Interventional

The Use of Nesiritide in Thoracic Aneurysm Repair to Prevent Acute Renal Failure

NCT00110201
View directory record Official record
Conditions
Cardiovascular Disease, Acute Renal Failure, Death
Interventions
Nesiritide
Drug
Lead sponsor
Ejaz, Abulate A, MD
Individual
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 14, 2026, 6:18 PM EDT
Completed Not applicable Interventional Results available

Will Veterans Engage in Prevention After HRA-guided Shared Decision Making?

NCT01828567
View directory record Official record
Conditions
Health Risk Appraisal, Heart Disease, Prevention
Interventions
Shared decision making with a Prevention Coach
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Ann Arbor, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 14, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

NCT02247739
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Recombinant human C1 inhibitor, Placebo
Biological · Other
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
13 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Tampa, Florida • St Louis, Missouri • Lake Oswego, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 14, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available

Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

NCT01756157
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
CINRYZE with rHuPH20
Biological
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 14, 2026, 6:18 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Project 2: ACHIEVE- HF

NCT05330221
View directory record Official record
Conditions
Heart Failure, Hypertension
Interventions
PAL2, PHARM-PAL2
Behavioral · Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 14, 2026, 6:18 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Donidalorsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
16
States / cities
Paradise Valley, Arizona • La Jolla, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 14, 2026, 6:18 PM EDT
Terminated Not applicable Interventional Results available

Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)

NCT00106938
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Stenosis, Stroke, Atherosclerosis
Interventions
Carotid artery stenting with filter (interventional), Carotid artery endarterectomy (surgical)
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
62
States / cities
Phoenix, Arizona • Mountain View, California • Newport Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 14, 2026, 6:18 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

E-Selectin Nasal Spray to Prevent Stroke Recurrence

NCT00012454
View directory record Official record
Conditions
Cerebrovascular Accident, Transient Ischemic Attack
Interventions
E-Selectin nasal spray
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Oct 14, 2026, 6:18 PM EDT
Completed Not applicable Interventional Results available

Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology

NCT01696760
View directory record Official record
Conditions
Bone Metastases, Musculoskeletal Cancer, Soft Tissue Sarcoma, Thromboembolism
Interventions
acetylsalicylic acid, enoxaparin, PCD
Drug · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 14, 2026, 6:18 PM EDT
Not listed No phase listed Observational

CarDiac MagnEtic Resonance for Primary Prevention Implantable CardioVerter DebrillAtor ThErapy: an International Registry (DERIVATE)

NCT03352648
View directory record Official record
Conditions
Heart Failure, Left Ventricular Systolic Dysfunction
Interventions
Not listed
Lead sponsor
Gianluca Pontone, MD, PhD
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 14, 2026, 6:18 PM EDT
Not yet recruiting Not applicable Interventional

Community Health Worker Support to Lower Blood Pressure After a Pregnancy With High Blood Pressure

NCT07778966
View directory record Official record
Conditions
Pregnancy-Associated Hypertension, Gestational Hypertension, Preeclampsia, Eclampsia, HELLP Syndrome, Postpartum Hypertension, Stage 2 Hypertension
Interventions
Alabama Womb to Heart Solution (AW2H) Community Health Worker (CHW) Program, Usual postpartum care with self-measured blood pressure education and home blood pressure monitor
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years to 56 Years · Female only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 14, 2026, 6:18 PM EDT
Withdrawn Phase 2 Interventional

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

NCT06352866
View directory record Official record
Conditions
Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Siltuximab, Teclistamab(FDA-approved)
Drug
Lead sponsor
Jack Khouri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 14, 2026, 6:18 PM EDT
Completed Phase 2 Interventional

Heart Disease on the Mend

NCT00127751
View directory record Official record
Conditions
Coronary Heart Disease, Stroke, Hyperlipidemia, Hypertension
Interventions
Enhance health lifestyle changes and medication compliance
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
35 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2005 · Synced Oct 14, 2026, 6:18 PM EDT
Completed Phase 3 Interventional Results available

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

NCT01231412
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hodgkin Lymphoma, Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Sirolimus, Total-Body Irradiation
Procedure · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
6
States / cities
Denver, Colorado • Atlanta, Georgia • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 14, 2026, 6:18 PM EDT
Not listed Phase 3 Interventional

Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms

NCT00934427
View directory record Official record
Conditions
Raynaud Disease
Interventions
0.9% nitroglycerin in TAM cream, vehicle cream
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Redwood City, California • Farmington, Connecticut • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2010 · Synced Oct 14, 2026, 6:18 PM EDT
Completed Not applicable Interventional

Hispanic Secondary Stroke Prevention Initiative

NCT02251834
View directory record Official record
Conditions
Stroke
Interventions
Community Health Worker (CHW), usual care and health education brochures every 4 months.
Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 14, 2026, 6:18 PM EDT
Completed Not applicable Interventional

Behavioral CVD Prevention Using Informatics

NCT02752464
View directory record Official record
Conditions
Health Behavior
Interventions
Counseling, feedback report
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 14, 2026, 6:18 PM EDT
Completed Phase 2 Interventional

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

NCT06299111
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
REGN9933, REGN7508, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 14, 2026, 6:18 PM EDT
Terminated Phase 3 Interventional

Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding

NCT00409084
View directory record Official record
Conditions
Esophageal Varices
Interventions
endoscopic variceal band ligation
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 5, 2010 · Synced Oct 14, 2026, 6:18 PM EDT